New treatment against tree pollen allergy based on contiguous overlapping peptides

• Research unit: INNOSUISSE
• Project number: 8566.1;7 LSPP-LS

Short description (English)

New treatment against tree pollen allergy based on contiguous overlapping peptides

Short description (French)

New treatment against tree pollen allergy based on contiguous overlapping peptides

Abstract (French)

The allergic population has risen dramatically in western countries over the last years up to almost 300 million people. . Today, allergy sufferers have the choice between pharmacological medications for symptom relief and several years¿ long desensitization, both therapies being prone to side effects. ANERGIS technology offers a new and convenient alternative, combining the efficacy of desensitization with increased safety. This novel immunotherapy is based on the use of allergen-derived contiguous overlapping peptides (COPs) inducing T-cell mediated tolerance without the risk of IgE elicited allergic responses. A product will be defined against tree pollen allergy and its development is planed up to phase IIa human clinical trial.